SCHEMBL23409854

SCHEMBL23409854

O=C(Cn1cc(-c2ccnc3ccccc23)c(-c2ccccn2)n1)NCc1ccccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 7/20 0.56
▸ MAPK14 Q16539 6/20 0.56
▸ CNR1 P21554 2/20 0.44
▸ ENPP2 Q13822 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ LMNA P02545 3/20 0.39
▸ AURKA O14965 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ F2 P00734 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29960223 1.00 TGFBR1 (0.56) TGFBR1MAPK14CNR1ENPP2KDM4E
SCHEMBL28822069 0.91 TGFBR1 (0.56) TGFBR1MAPK14ALDH1A1LMNAAURKA
SCHEMBL29959800 0.89 TGFBR1 (0.58) TGFBR1MAPK14CNR1RAB9AHPGD
SCHEMBL23409679 0.89 TGFBR1 (0.58) TGFBR1MAPK14CNR1RAB9AHPGD
SCHEMBL23409669 0.89 TGFBR1 (0.56) TGFBR1MAPK14AURKAAURKBMAPT
SCHEMBL29959791 0.89 TGFBR1 (0.56) TGFBR1MAPK14AURKAAURKBMAPT
SCHEMBL23409675 0.89 TGFBR1 (0.67) TGFBR1MAPK14KDM4ERAB9A
SCHEMBL29959983 0.89 TGFBR1 (0.67) TGFBR1MAPK14KDM4ERAB9A
SCHEMBL28822077 0.88 TGFBR1 (0.59) TGFBR1MAPK14CNR1ENPP2LMNA
SCHEMBL28822071 0.88 TGFBR1 (0.69) TGFBR1MAPK14CNR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US claimed
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Agomab Spain, S.L.U. (ES) 2025-05-13 — — US claimed
CN-114787145-B Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2024-03-26 — — CN claimed
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 Agomab Spain, S.L.U. (ES) 2023-01-26 — — US claimed
EP-4065572-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Origo Biopharma, S.L. (ES) 2022-10-05 — — EP claimed
CN-114787145-A Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 奥里戈生物制药有限公司 2022-07-22 — — CN claimed
WO-2021105317-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 ORIGO BIOPHARMA, S.L. (ES) 2021-06-03 — — WO claimed
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US disclosed
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Agomab Spain, S.L.U. (ES) 2025-05-13 — — US disclosed
CN-114787145-B Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2024-03-26 — — CN disclosed
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 Agomab Spain, S.L.U. (ES) 2023-01-26 — — US disclosed
CN-114787145-A Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 奥里戈生物制药有限公司 2022-07-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885CNR1 549/4885
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885CNR1 549/4885
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885CNR1 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback